2011 Scrip 100: Will Dilma be good for pharma?
This article was originally published in Scrip
Luiz Inacio Lula da Silva (Lula) will step down as President of Brazil in January 2011 after steering his country into a new era of stability and prosperity. Now, as his protégé Dilma Rousseff prepares to take over, there is a wide expectation amongst those same commentators that she will continue the fiscally-responsible strategies of her mentor. Mark Hollis examines the likely implications for the pharmaceutical industry.